GlassScriptPhysician profile
Bethany Davis
NPI 1205459310
$3,847.20
in general payments reported to CMS, 2019-2025
24 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $862 · 2022: $1,042 · 2023: $894 · 2024: $537 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,943.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $895.64 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $555.20 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $457.70 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $362.46 | 2022-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $340.29 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $274.91 | 2021-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $156.82 | 2021-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $138.88 | 2021-2023 | Ingrezza |
| Lundbeck LLC | $129.70 | 2021-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $89.40 | 2025 | Cobenfy |
| Indivior INC. | $73.72 | 2022-2025 | Sublocade |
| Almatica Pharma LLC | $58.58 | 2022-2025 | Loreev Xr |
| Sunovion Pharmaceuticals INC. | $55.31 | 2021 | |
| Corium, LLC | $33.58 | 2022-2024 | Azstarys |
| Sage Therapeutics, LLC | $31.68 | 2024-2025 | Zurzuvae |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30.14 | 2022-2023 | Belsomra |
| Axsome Therapeutics, INC. | $26.18 | 2023 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $24.44 | 2025 | Austedo Xr |
| Ironshore Pharmaceuticals INC. | $23.96 | 2022 | |
| Braeburn INC. | $20.34 | 2023 | Brixadi |
| Alfasigma USA, INC. | $19.90 | 2022 | |
| Neuronetics, INC. | $18.11 | 2021 | |
| Eisai INC. | $16.93 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.33 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.